Neural Inhibition as a Mechanism of Nicotine Dependence Among Persons With Schizophrenia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cigarette smoking decreases life expectancy, causes devastating health complications, and costs society billions of dollars each year. These untoward consequences are especially pronounced among persons with schizophrenia (SCZ) because approximately 80% to 95% of this group smokes cigarettes. These high prevalence rates underscore the need for research investigating the determinants of smoking in patients with SCZ. Several researchers have observed that nicotine improves specific symptoms of SCZ including negative symptoms, negative affect, and cognitive deficits. This has led to the hypothesis that patients with SCZ smoke in an attempt to self-medicate. However, the mechanism(s) by which nicotine has its positive effect on symptoms remains unclear. The current proposal posits that neural inhibition (NI) is a physiological mechanism of this effect, while variation in the alpha-7-nicotinic receptor subunit gene (CHRNA7) represents the genetic underpinnings of these processes. The proposed study will assess NI and symptom improvement after acute administration of nicotine to both smokers and nonsmokers with SCZ. In addition, NI and CHRNA7 variation will be tested as predictors of patients' ability to reduce/quit smoking following smoking treatment. These data may lead to the development of new pharmacological strategies for treating the symptoms of SCZ and new methods for assisting these patients to quit smoking.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Nicotine on Areas of Impaired and Preserved Functioning in Schizophrenia

NCT01034085

Nicotine Dependence Schizophrenia

COMPLETED

The Effects of Nicotine on Cognition in Schizophrenia

NCT00383747

Schizophrenia

COMPLETED PHASE4

Influence of Nicotine on Cognitive Function in Schizophrenic Patients With and Without Comorbid Drug Dependence

NCT01037075

Schizophrenia Drug Abuse/Dependency

COMPLETED

Cigarette Smoking in Smokers With and Without Schizophrenia

NCT04001114

Tobacco Dependence Schizophrenia

COMPLETED NA

fMRI Study of Nicotinic Effect on Neurophysiology of Schizophrenia

NCT01046526

Schizophrenia Psychopathology Nicotine Dependence

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The prevalence of smoking is unusually high among patients with SCZ. In light of the negative health, economic, and social consequences of smoking, treatment efforts in this area are imperative. Such efforts rest, in part, on an improved understanding of the underlying causes of smoking within this unique population. For example, several lines of research have indicated that smoking improves specific SCZ-related symptoms (i.e., negative psychotic symptoms, negative affect, cognitive deficits) and that patients may smoke to self-medicate with nicotine. However, the mechanism(s) underlying this effect are unknown. The current proposal posits that improved NI may be one such mechanism. More specifically, NI is conceived as a mediator of the relationship between smoking and symptom improvement. Also, given its proposed mechanistic nature, we believe that nicotine-related changes in NI may predict quit/reduction and/or relapse rates following a smoking cessation program. Additionally, variants of CHRNA7 likely represent the genetic underpinnings of decreased NI, vulnerability to smoking, and smoking treatment resistance among patients with SCZ. These hypotheses are supported by previous experiments that suggest: (1) patients with SCZ have decreased NI (Adler et al., 1998); (2) nicotine administration (via its effects on the alpha-7-nicotinic receptor, which, in turn activates GABAergic interneurons) enhances NI in these patients (Adler et al., 1998); (3) genetic variation in the alpha-7-nicotinic receptor increases risk for smoking among patients with SCZ (Leonard et al., 1996); and, (4) higher levels of NI are associated with fewer negative symptoms, less negative affect, and better cognition (Yee et al., 1998). However, these studies have been hampered by several methodological and conceptual shortcomings including small sample sizes, the presence of confounding variables (e.g., the effects of nicotine withdrawal), and limited testing of relevant symptom domains. Furthermore, previous studies have examined only isolated aspects of the proposed model, leaving many of the central relationships between variables untested and speculative. The current proposal seeks to rectify these methodological issues within the context of a multidisciplinary scientific team. Globally, its objectives are twofold. First, to replicate and extend previous findings that nicotine causes symptom attenuation. Second to investigate the underlying neurophysiological and genetic mechanisms of these effects. The specific objectives and hypotheses addressed in this study are as follows:

1. To acutely administer nicotine versus placebo to smokers with SCZ following transient abstinence from cigarettes, in order to investigate the effect of nicotine on the SCZ symptoms. This objective extends previous research by employing an adequately large sample and simultaneously testing several relevant domains of symptom improvement. Hypothesis: Significantly greater improvements across the domains of negative symptoms, negative affect, and cognitive deficits will be evident among those patients receiving nicotine versus placebo.
2. To acutely administer nicotine versus placebo to nonsmokers with SCZ in order to investigate the effects of nicotine on the symptoms of SCZ, independent of withdrawal. This objective allows for the methodological disambiguation of the direct neural effects of nicotine from the effects of termination of withdrawal symptoms. Additionally, this will provide seminal data regarding the acute treatment benefits of nicotine as a therapeutic agent, delivered without the health risks associated with smoking. Hypothesis: Significantly greater improvements across all symptoms domains will be evident among those patients receiving nicotine versus placebo.
3. To ascertain (using statistical techniques outlined by Kenny and others) (Baron \& Kenny, 1986; Judd \&Kenny, 1981) whether the relationship between acute nicotine administration and symptom reductions is mediated by increased NI (as measured via ERP and TMS paradigms). Hypothesis: NI will meet the statistical criteria for mediating the relationship between nicotine administration and symptom reductions.
4. To ascertain whether nicotine-related changes in NI predict patients' ability to reduce smoking, the amount of nicotine replacement therapy (NRT) required, and rates of quitting and smoking relapse following completion of a smoking cessation program. Hypothesis: NI will operate as a significant and unique predictor of the amount of smoking reduction and NRT use, as well as quit and relapse rates, over and above conventional predictors of smoking reduction from the general population (i.e., age, marital status, coping resources, socioeconomic status, smoking related health problems, the number of cigarettes smoked per day, concomitant alcohol and coffee consumption, treatment compliance, and stage of change) (Matheny \& Weatherman, 1998; Ockene et al., 2000; Oritz et al., 2003).
5. To investigate whether polymorphisms in CHRNA7 are associated with the magnitude of NI deficits, symptom reductions following acute nicotine administration, rates of smoking among patients with SCZ, and/or quit/reduction or relapse rates following smoking cessation treatment. Hypothesis: Significant genetic association will be demonstrated between CHRNA7 polymorphisms and each of the above-listed clinical variables.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Smoking Nicotine Dependence Schizophrenia Schizophreniform Disorders Schizoaffective Disorder Psychosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1A

Group Type EXPERIMENTAL

Nicotine patch

Intervention Type DRUG

21 mg of nicotine via a dermal patch

1B

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type OTHER

placebo via a dermal patch

2A

Group Type EXPERIMENTAL

smoking cessation group therapy

Intervention Type BEHAVIORAL

a 9-week group based on the "Freedom From Smoking" program designed by the American Lung Association. The treatment was manualized and modified to meet the functional and cognitive capabilities of patients with psychotic disorders

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nicotine patch

21 mg of nicotine via a dermal patch

Intervention Type DRUG

placebo

placebo via a dermal patch

Intervention Type OTHER

smoking cessation group therapy

a 9-week group based on the "Freedom From Smoking" program designed by the American Lung Association. The treatment was manualized and modified to meet the functional and cognitive capabilities of patients with psychotic disorders

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Voluntary and competent to consent
* Have a diagnosis of schizophrenia, schizophreniform, or schizoaffective disorder as confirmed by the Structured Clinical Interview for the DSM-IV (SCID-IV)
* Between the ages of 18 and 60

Exclusion Criteria

* Have a DSM-IV history of substance abuse or dependence (other than caffeine or nicotine) in the last 6 months
* Have a self-reported concomitant major medical or neurologic illness
* Pregnant
* Currently prescribed medications known to deleteriously affect cognition (e.g., benzodiazepines, tricyclic anti-depressants, anticholinergics, MAO inhibitors, GABA-B agonists)
* Currently taking clozapine (due to its documented effect on both NI and smoking
* Report suffering from conditions that may be aggravated by acute nicotine administration (e.g., arrhythmias, recent myocardial infarction)

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes